FDA: Here’s Yet Another Blood Pressure Medication Recall For Cancer Concerns

Healthcare FDA: Here’s Yet Another Blood Pressure Medication Recall For Cancer Concerns Bruce Y. Lee Senior Contributor Opinions expressed by Forbes Contributors are their own. I am a writer, journalist, professor, systems modeler, computational and digital health expert, avocado-eater, and entrepreneur, not always in that order.

Following New! Follow this author to stay notified about their latest stories. Got it! Oct 30, 2022, 01:18am EDT | New! Click on the conversation bubble to join the conversation Got it! Share to Facebook Share to Twitter Share to Linkedin This time the company is Aurobindo Pharma USA, Inc. The blood pressure medication being recalled is .

. . [+] Quinapril and Hydrochlorothiazide Tablets USP in 20 mg and 12.

5 mg doses, respectively. And the contaminant is Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Quinapril in levels that exceed acceptable limits. (Photo by Christoph Soeder/picture alliance via Getty Images) dpa/picture alliance via Getty Images In the words of Daft Punk, one more time.

On October 25, the U. S. Food and Drug Administration (FDA) announced yet another blood pressure medicine recall for contaminants that may cause cancer, a problem that has occurred far too many times since 2017.

This time the company is Aurobindo Pharma USA, Inc. The blood pressure medication being recalled is Quinapril and Hydrochlorothiazide Tablets USP in 20 mg and 12. 5 mg doses, respectively.

And the contaminant is Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Quinapril in levels that exceed acceptable limits. Here’s a tweet from the FDA with a picture of the label for the medication: This certainly isn’t a “we’re gonna celebrate” situation. Although nitrosamines can be found in water and foods such as cured and grilled meats, dairy products, and vegetables, ingesting nitrosamines repeatedly over a long periods of time can increase your risk of cancer.

That’s why the FDA has established thresholds for accpeptable levels of nitrosamines in medication. Although there haven’t yet been any reports of adverse events related to the medications being recalled by Aurobindo Pharma USA, Inc. so far, the presence of too high levels of nitrosamines means that the company is gonna have to do it right and do some cleaning of its manufacturing processes.

So check your blood pressure medications. The recall doesn’t encompass all blood pressure medications under the sun or the moon for that matter. It just includes specific lots of the Quinapril and Hydrochlorothiazide Tablets USP 20 mg/12.

5 mg shipped by Aurobindo Pharma USA, Inc. And these lots are numbered either the QE2021005-A or QE2021010-A and were shipped sometime from May 2021 onwards. You can check the medication label for the national drug code (NDC) number 65862-162-90 and an expiry date of 01/2023 on the label.

The tablets are pink-colored, round-shaped, biconvex, and film-coated with a “D” imprinted on one side and a “19”on the other side. If you still can’t figure out whether your medications fall within the recall, call the pharmacist that provided you with the medications. Should your medications fall within the recall, don’t stop them immediately.

Blood pressure medications aren’t like hot dogs. You may not be able to quit them cold turkey or rather cold hot dog. Abruptly stopping your blood pressure medication could lead to unsafe spikes in your blood pressure.

So contact your doctor as soon as possible to get guidance as to what to do first. Once you and your doctor decide what to do you should be able to return the medications for a refund. You may actually get a call from Qualanex, on behalf of Aurobindo Pharma USA, Inc.

, if they realize that you are using medications that fall within the recall. So if they do call you, don’t simply say, “hey, I don’t want what you are selling” or “I thought I had quit that dating app a long time ago. ” Instead, listen to what they have to say.

MORE FOR YOU The Inside Story Of Papa John’s Toxic Culture Ferrari Returns To The Top Of Sports Car Racing With The Hybrid 499P Hypercar Why Q3’s GDP Print Doesn’t Mean Recession Avoidance If this all seems like déjà vu all over again, it is. It’s actually déjà vu of déjà vu of déjà vu. I’ve already covered for Forbes similar blood pressure medication recalls by Pfizer in March 2022 , by Lupin Pharmaceuticals Inc.

, in October 2021 , by Torrent Pharmaceuticals Limited in September 2019 , by Hetero Labs Ltd in May 2019 , and by a bunch of other companies in 2018 . As they say, once can be an accident. Twice may be a coincidence.

Three times is not a lady but a pattern. And four, five, six, and many more times means that more needs to be done. This latest blood pressure medication recall is a reminder one more time that more needs to be done to determine how safe our medication supplies are.

With pharmaceutical manufacturers expanding their supply chains globally and trying to find lower cost ways of manufacturing medications, you’ve gotta wonder how well regulations are being applied and processes are being monitored. The consequences of screwing up manufacturing of medications is whole lot greater than screwing up the manufacturing of hoodies. Even if your hoodie had some extra hoods or came in the wrong color like a bright urine yellow, the problems would be readily noticeable and reversible.

So what if that person didn’t want to date you simply because you had four hoods on your hoodie and looked like a gigantic daffodil. Medication defects by contrast may not be as easily recognizable and can cause lots of untoward health effects. Not doing more to address and prevent carcinogenic contaminants from tainting medications would be daft indeed.

Follow me on Twitter or LinkedIn . Check out my website . Bruce Y.

Lee Editorial Standards Print Reprints & Permissions.